About Us
Our Vision
our objectives
our mission
Molecular medicine, i.e. therapeutic proteins, gene therapies, and cell therapies, have progressed exponentially in the last two decades. However, most do not support a sustainable model for health-care, and the majority of patients in the developing world could not afford them. Our vision is to improve the affordability and accessibility
Molecular medicine, i.e. therapeutic proteins, gene therapies, and cell therapies, have progressed exponentially in the last two decades. However, most do not support a sustainable model for health-care, and the majority of patients in the developing world could not afford them. Our vision is to improve the affordability and accessibility of essential modern medicines by developing innovative scientific solutions that can promote sustainable business strategies and pricing models.
our mission
our objectives
our mission
Cold chain dependence limits the accessibility of proteins and substantially alleviates the cost of logistics and storage. Further, it is an extra variable for pharma companies, which is difficult to manage during quality control procedures. Our first mission is to reduce the dependence of protein biologics on the cold chain for transport
Cold chain dependence limits the accessibility of proteins and substantially alleviates the cost of logistics and storage. Further, it is an extra variable for pharma companies, which is difficult to manage during quality control procedures. Our first mission is to reduce the dependence of protein biologics on the cold chain for transportation and storage. This will comfortably bring down the cost by 20 percent and significantly increase the accessibility and ease of logistics in developing nations.
our objectives
our objectives
our technologies
In sync with our mission, the company has developed its first product InsulinStrong. Insulin is a therapeutic protein and an essential medicine to manage diabetes. InsulinStrong is a crystalline form of recombinant human Insulin (rhI) which is refrigeration independent. This molecule is stable at high temperatures and has a shelf life of
In sync with our mission, the company has developed its first product InsulinStrong. Insulin is a therapeutic protein and an essential medicine to manage diabetes. InsulinStrong is a crystalline form of recombinant human Insulin (rhI) which is refrigeration independent. This molecule is stable at high temperatures and has a shelf life of two years at room temperature.
Our primary objective for the next 18 months is to complete the preclinical studies and develop standard operating protocols for 10-liter scale production in GMP conditions. Our first major milestone will be to file IND applications (at CDSCO, FDA, and EMA) to initiate clinical studies under biosimilar/follow-on category for InsulinStrong
Our secondary objective for the next 12 months is to create a proof of concept for four more clinical verticals (a viral vaccine, Glargine (Insulin analog) & a Monoclonal antibody).
our technologies
our business design
our technologies
Lamark biotech counts on its R&D capabilities and founders with decades of experience in the field of molecular science. Our passionate team has published research articles in protein chemistry, protein structure analysis, Cell & Molecular biology. The team has developed platforms to produce extra stable proteins (patent pending) and inno
Lamark biotech counts on its R&D capabilities and founders with decades of experience in the field of molecular science. Our passionate team has published research articles in protein chemistry, protein structure analysis, Cell & Molecular biology. The team has developed platforms to produce extra stable proteins (patent pending) and innovative biochemical assays to analyze functional and structural properties at a molecular level.
our partnerships
our business design
our business design
We are working collaboratively with multiple companies, research labs, and market research experts. Lamark Biotech will carry out R&D activities at VIT-TBI, Vellore Institute of Technology, Vellore, India. The company has collaboration with CrystalGel S.L. our technology partner, Spain, and Inqognito our market research partners, India, c
We are working collaboratively with multiple companies, research labs, and market research experts. Lamark Biotech will carry out R&D activities at VIT-TBI, Vellore Institute of Technology, Vellore, India. The company has collaboration with CrystalGel S.L. our technology partner, Spain, and Inqognito our market research partners, India, cGMP production, and clinical studies Andalusian Initiative for Advanced Therapies (IATA), Spain. We are a B2B company and trying to collaborate with pharma companies for API manufacturing, clinical studies & marketing. Together we expect to place the refrigeration independent InsulinStrong on the shelf of every pharmacy outlet before 2030.
On the other hand, Lamark is creating strategic alliances with public institutions (University of Granada, CMC Vellore, St johns hospital, Bangalore; AIIMS, Delhi; and Narayan Netralay, Bangalore) and private (Biocon, Genei, Bharat Biotech, and GSK).
our business design
our business design
our business design
Our business model is based on research and development of technologies for clinical-grade molecular medicine. Our channels of revenue are technology licensing to pharma companies (B2B) and at later stages retail marketing of products to patients and hospitals (B2C). For B2B sales, we meet executive boards and chief scientific officers of
Our business model is based on research and development of technologies for clinical-grade molecular medicine. Our channels of revenue are technology licensing to pharma companies (B2B) and at later stages retail marketing of products to patients and hospitals (B2C). For B2B sales, we meet executive boards and chief scientific officers of pharma companies. A series of meetings are followed to develop understanding and create collaborations for the development of thermostable formulations from existing drug substances from the client. For B2C, we plan to adapt our revenue models based on the demand and demographics of the market. Our marketing plan is to convincingly communicate the influencers, i.e. doctors and hospital staff, who play a significant role in the choice of the brand. Besides, we will create patient consortiums in small cities to help patients share their experiences with others.